In contrast to breast and gastric cancers, anti-HER2 treatments are not a standard of care for NSCLC management, despite recent promising results with HER2 antibody-drug conjugates such as trastuzumab-deruxtecan (5, 6). The gene discussed is ERBB2; the disease is gastric cancer.